St. Jude Medical introduces first commercial implants of DRG stimulation therapy in US

11 April 2016 (Last Updated April 11th, 2016 18:30)

Medical device company St. Jude Medical has introduced the first post-approval implants of its axium neurostimulator system for dorsal root ganglion (DRG) stimulation.

DRG

Medical device company St. Jude Medical has introduced the first post-approval implants of its axium neurostimulator system for dorsal root ganglion (DRG) stimulation in the US.

The technology is used to treat patients afflicted with chronic pain that is hard to control coupled with traditional spinal cord stimulation (SCS).

The DRG stimulation is a spinal structure which is densely composed of sensory nerves that relays information to the brain via the spinal cord, allowing physicians to treat the specific areas of the body where pain occurs.

The first commercial implants of the device were used at the Center for Pain Relief in Charleston by Dr Timothy Deer, and by Dr Jason Pope at the Sutter Santa Rosa Surgery and Endoscopy Center in Santa Rosa.

St. Jude's axium neurostimulator system is a therapeutic treatment to heal moderate to severe chronic intractable pain of the lower limbs in adult patients with complex regional pain syndrome (CRPS).

According to Dr Pope, the chronic pain can be attributed to complications during recovery from surgeries such as knee arthroscopy, foot surgery or hernia surgery.

Deer said: "Adding dorsal root ganglion stimulation with the Axium neurostimulator system to my therapeutic arsenal is an exciting step in the treatment of chronic intractable pain of the groin, knee and foot.

"I am impressed with the speed in which I am able to reach and stimulate the dorsal root ganglion, something I was unable to do before the Axium neurostimulator system.

"For the first time, I now have a device designed specifically for the large and growing number of under-treated chronic pain patients I could not previously serve."

"For the first time, I now have a device designed specifically for the large and growing number of under-treated chronic pain patients I could not previously serve."

The initial results of the ACCURATE IDE study, has projected better pain relief of the patients after being administered of the DRG stimulation.

DRG stimulation was approved with the St. Jude Medical Axium Neurostimulator System based in part on the results of this study, in which patients were randomly subjected to DRG stimulation delivered by the Axium neurostimulator system or traditional tonic spinal cord stimulation (SCS) therapy delivered by the competitors.

St. Jude Medical is collaborating with implanting chronic pain specialists to implement the DRG implants in more than 100 procedures in 59 centers nationwide in the first month after launch.


Image: The St. Jude Medical Axium Neurostimulator System. Photo: courtesy of Business Wire.